Novozymes A/S (OTCMKTS:NVZMY) Cut to "Hold" at Zacks Research

Key Points

• Novozymes A/S has been downgraded from a "strong-buy" rating to a "hold" rating by Zacks Research, reflecting a more cautious outlook for the company.
• The company's stock opened at $62.57 and has a market capitalization of $29.30 billion, indicating its significance in the industrial enzymes market.
• Novozymes A/S specializes in producing industrial enzymes and probiotics for various sectors, including the food and beverage industry and hygiene products.

Novozymes A/S (OTCMKTS:NVZMY - Get Free Report) was downgraded by research analysts at Zacks Research from a "strong-buy" rating to a "hold" rating in a research report issued on Monday,Zacks.com reports.

Novozymes A/S Price Performance

NVZMY opened at $62.57 on Monday. Novozymes A/S has a 12-month low of $53.95 and a 12-month high of $75.99. The company has a current ratio of 1.66, a quick ratio of 1.04 and a debt-to-equity ratio of 0.11. The business's fifty day simple moving average is $68.58 and its 200-day simple moving average is $65.06. The company has a market capitalization of $29.30 billion, a price-to-earnings ratio of 39.60, a PEG ratio of 1.18 and a beta of 0.90.

Novozymes A/S Company Profile

Novozymes A/S produces and sells industrial enzymes, microorganisms, and probiotics in Denmark, rest of Europe, North America, Asia Pacific, the Middle East, Africa, Latin America, and internationally. The company offers protein solutions for the food and beverage industry. It also offers industrial hygiene, drain openers, hard surface, medical cleaning, septic tanks, ware washing, and professional laundry services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.